MedPath

Efficacy of inhaled DNase in children with an airway malacia and a lowerrespiratory tract infection.

Completed
Conditions
Tracheobronchomalacia and a lower respiratory tract infection
Registration Number
NL-OMON20292
Lead Sponsor
Erasmus MC-Sophia Children's Hospital
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

1. Children aged 2-18 years with tracheobronchomalacia (diagnosed bronchoscopically);

2. Symptoms of a lower respiratory tract infection.

Exclusion Criteria

1. Indication for a course of antibiotics at presentation (assessed by pediatric pulmonologist);

2. Co-existing chronic pulmonary disease (e.g. cystic fibrosis, broncho pulmonary dysplasia or primary ciliary dyskinesia);

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Decrease in mean daily Cough Symptom Score (CSS).
Secondary Outcome Measures
NameTimeMethod
1. Need for additional antibiotics;<br /><br>2. Mean daily cough severity” and coughability of sputum” (VAS-score);<br /><br>3. CSS and VAS on each treatment day;<br /><br>4. Lung function (FEV1, FVC, PEF, MEF25, RINT);<br /> <br>5. Parent’s perception about treatment efficacy;<br /> <br>6. Doctor’s diagnosed end of infection after 1 and 2 weeks treatment.
© Copyright 2025. All Rights Reserved by MedPath